Companies · Biotechnology

Ascent Industries Corp.

MAPLE RIDGE · Biotechnology

Diligence memoA one-page analyst read on Ascent Industries Corp. — recommendation, valuation, rhythm, risks.
$477K
Total raised · real
1
Rounds
1.0×
Latest step-up
Top 91%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Wed Dec 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Ascent Industries Corp. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.24× the median modeled value of Pre-Seed Biotechnology companies in 2016–2018 (152 peers) — value vs value, same stage and era.
  • Within the normal band (124% of peer median) for its niche.
Dormant
  • Last raise 8.5 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Ascent Industries Corp. is one of 4293 Biotechnology companies tracked from MAPLE RIDGE. By capital raised it ranks in the long tail (ahead of 10% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
9
Investors (latest)
2013
Year incorporated
2017-12-20
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2017-12-20 Raised $457K (real) Modeled valuation $25M (est)$457K$25MPre-Seed2017Pre-Seed · 2017-12-20 Raised $457K (real) Modeled valuation $25M (est)$457K$25MPre-Seed2017Pre-Seed · 2017-12-20 Raised $477K (real) Modeled valuation $26M (est)$477K$26MPre-Seed2017+$457K+$477KCumulative $1.4M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$457K · 2017
Pre-Seed extension$457K · 2017
Pre-Seed extension$477K · 2017

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$26.3M
Base estimate est.
$254K
Conservative case
$298.4M
Upside case
$2.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $25.2M · 2017-12-202017Pre-Seed · modeled $25.2M · 2017-12-20Pre-Seed · modeled $26.3M · 2017-12-202017
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
8.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
8.5 yr
On record since
2017
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$477K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.2× above median
This company$477K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.4× of median
This company$26.3M
Sector median$64.2M

Raised more than 10% of sector peers (real $). Modeled value above 32% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #64 of 152.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)New Vital Signs, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Cerebral Magnetics INC · Pre-Seed Raised $1.0M · modeled $55.2M (est)NutriBand Inc. · Pre-Seed Raised $1.2M · modeled $55.2M (est)Jivana Biotechnology Inc · Pre-Seed Raised $2.0M · modeled $55.2M (est)AnTolRx, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)US Biologic, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Zeta Biolongevity, Inc. · Pre-Seed Raised $995K · modeled $54.9M (est)ALRGN Bio, Inc. · Pre-Seed Raised $946K · modeled $52.2M (est)Cellsolutions Llc · Pre-Seed Raised $1.9M · modeled $49.7M (est)BioSurfaces, LLC · Pre-Seed Raised $900K · modeled $49.7M (est)Pique Therapeutics, Inc. · Pre-Seed Raised $1.4M · modeled $47.2M (est)Gradient Pharmaceuticals, Inc. · Pre-Seed Raised $850K · modeled $46.9M (est)Ascent Industries Corp. (this company) Raised $477K · modeled $26.3M (est)Ascent Industries Corp.
CompanyStageRaised · realValue · estvs peer med.
New Vital Signs, Inc.Pre-Seed$1.0M$55.2M2.61×
Cerebral Magnetics INCPre-Seed$1.0M$55.2M2.61×
NutriBand Inc.Pre-Seed$1.2M$55.2M2.61×
Jivana Biotechnology IncPre-Seed$2.0M$55.2M2.61×
AnTolRx, Inc.Pre-Seed$1.0M$55.2M2.61×
US Biologic, Inc.Pre-Seed$1.0M$55.2M2.61×
Zeta Biolongevity, Inc.Pre-Seed$995K$54.9M2.60×
ALRGN Bio, Inc.Pre-Seed$946K$52.2M2.47×
Cellsolutions LlcPre-Seed$1.9M$49.7M2.35×
BioSurfaces, LLCPre-Seed$900K$49.7M2.35×
Pique Therapeutics, Inc.Pre-Seed$1.4M$47.2M2.23×
Gradient Pharmaceuticals, Inc.Pre-Seed$850K$46.9M2.22×
Ascent Industries Corp. this companyPre-Seed$477K$26.3M1.24×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$457K2017-12-20$2.5M$25.2M90%
Pre-Seed$457K2017-12-20$2.5M$25.2M90%
Pre-Seed$477K2017-12-20$2.6M$26.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$457K2017-12-20
    • First recorded raise — entered as Pre-Seed.
    • 9 investors on this round.
  2. Pre-Seed$457K2017-12-20
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 9 investors on this round.
  3. Pre-Seed$477K2017-12-20
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 9 investors on this round.
Intelligence
Modeled next raise
$497K
Modeled next size est.range $477K$795K
1.0×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Andrew Robinson4 other2017-12
Drew Malcolm2017-12
James Poelzer2017-12
Mark Parr2017-12
Philip Campbell2017-12
Reid Parr2017-12
Registry & provenance

Ascent Industries Corp. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1725861
SEC CIK
2013
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Ascendant Diagnostics LLCBiotechnologyPre-Seed$477K$26.3Msame sector · same stage
Intervene Immune, Inc.BiotechnologyPre-Seed$471K$26.0Msame sector · same stage
Smartech Topical, Inc.BiotechnologyPre-Seed$488K$26.9Msame sector · same stage
Thera Test Laboratories IncBiotechnologyPre-Seed$490K$27.1Msame sector · same stage
XRad Therapeutics, Inc.BiotechnologyPre-Seed$499K$27.5Msame sector · same stage
Aidia Investment Group, Inc.BiotechnologyPre-Seed$500K$27.6Msame sector · same stage
Alexandria Research Technologies, LLCBiotechnologyPre-Seed$500K$27.6Msame sector · same stage
Biotech Holdings, LLCBiotechnologyPre-Seed$500K$27.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Expansion Technologies, Inc.BiotechnologySeed$66.6M86%
Overture Life, Inc.BiotechnologySeries A$491.7M85%
Everest Biolabs, Inc.BiotechnologySeries A$10.3M84%
Elevai Labs Inc.BiotechnologySeed$1.9M83%
Steep Hill, Inc.BiotechnologySeries A$144.6M83%
DrugCendR Inc.BiotechnologySeed$48.8M83%
Endeavor Biomedicines, Inc.BiotechnologySeries D+$1.6B83%
Achieve Life Sciences, Inc.BiotechnologySeries B$270.0M83%
Frequently asked
How much funding has Ascent Industries Corp. raised?
Ascent Industries Corp. has raised approximately $477K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Ascent Industries Corp.'s estimated valuation?
Provath's modeled valuation for Ascent Industries Corp. is approximately $26.3M (modeled range $254K–$298.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Ascent Industries Corp. at?
Ascent Industries Corp.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Wed Dec 20.
What does Ascent Industries Corp. do and where is it based?
Ascent Industries Corp. operates in the Biotechnology sector, based in MAPLE RIDGE.
Explore related

See where Ascent Industries Corp. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Ascent Industries Corp., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.